BioCentury
ARTICLE | Company News

Vicuron's dalbavancin delayed

May 12, 2005 12:45 AM UTC

Vicuron (MICU; NMerc:MICU) said FDA extended the PDUFA date for dalbavancin to treat complicated skin and soft tissue infections (cSSTIs) by three months to Sept. 21. The original PDUFA date for the o...